Stomatitis News and Research

RSS

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Researchers investigated the mutations reported in the Omicron variant and its likely impact on the use of therapeutic antibodies in COVID-19 treatment as well as on vaccinated individuals.

17 Dec 2021

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

A new study found that the Omicron S protein evades antibodies with a 44-fold higher efficiency than the Delta variant's spike, rendering therapeutic antibodies ineffective and likely negatively impacting antibody protection induced by infection or double vaccination.

16 Dec 2021

Evaluation of SARS-CoV-2 Omicron's immune evasion potential

Researchers use VSV vector and Omicron spike protein containing all 32 mutations to create the pseudotyped SARS-CoV-2 Omicron variant (PV-Omicron).

15 Dec 2021

Study finds sarbecoviruses circulating in wildlife outside Asia can infect human cells

A recent study tested the RBD of 2 sarbecoviruses found in Russian horseshoe bats and other clades 3 viruses for their ability to invade the human cell.

10 Dec 2021

Glycosylation and disulfide bonding profile of SARS-CoV-2 spike glycoprotein

Researchers found that virus-like particles produced by co-expression of SARS-CoV-2 S, membrane, envelope, and nucleocapsid proteins contain S glycoproteins, which are modified by complex carbohydrates.

29 Nov 2021

SARS-CoV-2 vaccine based on vesicular stomatitis virus exhibits high neutralizing efficacy against variants

Scientists have tested the efficacy of BriLife®-vaccinated human sera in neutralizing more infectious and probably more virulent SARS-CoV-2 variants.

26 Nov 2021

The role of CRISPR in viral diagnostics

A comprehensive review explains in depth how CRISPR can be utilized as a reliable tool to investigate the viral life cycles.

29 Oct 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

A new study identifies a potent SARS-CoV-2 antiviral, Pheophorbide a (PheoA), which is a compound derived from the plant Marchantia polymorpha L.

27 Oct 2021

Study finds FDA-approved drug has potent antiviral activity against SARS-CoV-2 and variants of concern

A new study aimed to examine the antiviral potential of atovaquone against the original SARS-CoV-2 strain and other variants of concern.

25 Oct 2021

Safety and oral immunogenicity of a VSV-derived mucosal vaccine against SARS-CoV-2

A team of researchers exploited the known tropism of vesicular stomatitis virus to develop an oral vaccine that expresses the immunogenic SARS-CoV-2 spike glycoprotein in the oral mucosa.

20 Oct 2021

Research may provide clues to how viral infections contribute to neurodegeneration

Some viral diseases could possibly contribute to neurodegeneration. DZNE researchers report this in the scientific journal "Nature Communications".

19 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.

30 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

New method for producing pseudotyped virus particles bearing spike protein of SARS-CoV-2

A new study discusses the development of an improved protocol based on cell lines that can consistently express S proteins.

5 Aug 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Study shows inhalable nanocatchers can protect lung cells against SARS-CoV-2

Inhalable nanocatchers that contain hACE2 have been recently developed by a group of researchers, providing a plethora of potential benefits in comparison to existing treatments against COVID-19.

27 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.

6 Jul 2021